FDA Chart.docx - As an example of a one-sided hypothesis...

This preview shows page 1 - 2 out of 3 pages.

As an example of a one-sided hypothesis, suppose we want to see if a new medicine is more successful than the existing standard, and all we care about is a substantial difference in mean response in one way (Fleming, 2015). Phase Purpose Subjects (How many and how selected) Type(s) of Study Design Used Phase I The first studies in animals and humans Rybelsus Patients with Type 2 diabetes were enrolled in the PIONEER 1 study. Oral semaglutide was given to 525 individuals in three doses once a day (3mg, 7mg, and 14 mg). A total of 178 individuals were recruited in the placebo study. Patients were excluded if they had had diabetic therapy during the previous 90 days. Tremfya Patients were randomly assigned to receive guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 329); placeboguselkumab (weeks 0, 4, and 12; n = 174); or adalimumab (80 mg week 0, 40 mg week 1, then 40 mg every 2 weeks until week 47; n = 334). Rybelsus The PIONEER set of trials looked at Rybelsus in 10 distinct ways. The PIONEER 1 study compared oral semaglutide to placebo in a randomized, double-blind experiment. This was a 26-week trial. Tremfya VOYAGE 1 (NCT02207231) was a phase III, randomized, double-blind, placebo- and active comparator–controlled study that took place in 101 different locations across the world (December 2014-April 2016). Phrase II To determine dosage, pharmaco-dynamics, short- term safety, effects Rybelsus The PIONEER 2 trial recruited 412 patients who received oral semaglutide 14 mg once daily and 410 individuals who received oral empagliflozin 25 mg once daily. If a patient has previously received additional medicine for diabetes or obesity, renal impairment, microvascular problems, or a pancreatitis diagnosis, they were excluded from the study.

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture